Next Article in Journal
Current Advances in Aptamers for Cancer Diagnosis and Therapy
Next Article in Special Issue
Post-Translational Modifications of H2A Histone Variants and Their Role in Cancer
Previous Article in Journal
Clinical Implementation of Robust Optimization for Craniospinal Irradiation
Previous Article in Special Issue
Ubiquitin Specific Peptidase 22 Regulates Histone H2B Mono-Ubiquitination and Exhibits Both Oncogenic and Tumor Suppressor Roles in Cancer
Article Menu
Issue 1 (January) cover image

Export Article

Open AccessReview

Modification of Epigenetic Histone Acetylation in Hepatocellular Carcinoma

Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan
Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung 80708, Taiwan
Author to whom correspondence should be addressed.
Cancers 2018, 10(1), 8;
Received: 13 November 2017 / Revised: 19 December 2017 / Accepted: 30 December 2017 / Published: 3 January 2018
(This article belongs to the Collection Histone Modification in Cancer)
PDF [432 KB, uploaded 3 January 2018]


Cells respond to various environmental factors such as nutrients, food intake, and drugs or toxins by undergoing dynamic epigenetic changes. An imbalance in dynamic epigenetic changes is one of the major causes of disease, oncogenic activities, and immunosuppressive effects. The aryl hydrocarbon receptor (AHR) is a unique cellular chemical sensor present in most organs, and its dysregulation has been demonstrated in multiple stages of tumor progression in humans and experimental models; however, the effects of the pathogenic mechanisms of AHR on epigenetic regulation remain unclear. Apart from proto-oncogene activation, epigenetic repressions of tumor suppressor genes are involved in tumor initiation, procession, and metastasis. Reverse epigenetic repression of the tumor suppressor genes by epigenetic enzyme activity inhibition and epigenetic enzyme level manipulation is a potential path for tumor therapy. Current evidence and our recent work on deacetylation of histones on tumor-suppressive genes suggest that histone deacetylase (HDAC) is involved in tumor formation and progression, and treating hepatocellular carcinoma with HDAC inhibitors can, at least partially, repress tumor proliferation and transformation by recusing the expression of tumor-suppressive genes such as TP53 and RB1. View Full-Text
Keywords: AHR; HDAC8; hepatocellular carcinoma AHR; HDAC8; hepatocellular carcinoma

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Liu, K.-Y.; Wang, L.-T.; Hsu, S.-H. Modification of Epigenetic Histone Acetylation in Hepatocellular Carcinoma. Cancers 2018, 10, 8.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top